Amgen Reports 9% Revenue Growth in Q2 2025 Amid Prolia Patent Expiry Challenges

U.S.-based biopharmaceutical company Amgen Inc. (NASDAQ: AMGN) announced its Q2 2025 financial report, with year-over-year revenue...Increase by 9% to Reach $9.2 Billion。Product sales increased by 13%., but affected by3% Negative Price Pressure Impact。

Main Product Performance

In this quarter, 15 brands achieved double-digit growth:

• Repatha(Repatha, Evolocumab): Used for treating high cholesterol, year-on-yearIncrease by 31%, Reach$696 million。

• For the treatment of osteoporosisEvenity(Romosozumab):Increase by 32%, Reach$518 million。

• Rare Disease Product Portfolio:Tepezza（teprotumumab）：Increase by 5%, Reach$505 million；Krystexxa（pegloticase）：Increase by 19%, Reach$349 million；Uplizna（inebilizumab）：Increase by 91%, Reach$176 million。

• Inflammation Product Portfolio: Asthma MedicationsTezspire（tezepelumab）：Increase by 46%, Reach$342 million; Autoimmune Disease TherapyOtezla（apremilast）：Increase by 14%, reaching$618 million。

• Oncology Portfolio: CD19 T Cell EngagerBlinatumomab（Blincyto，blinatumomab）：Increase by 45%, reaching$384 million。

Growth Lagging Products

Enbrel (Etanercept): Sales of this autoimmune disease drug fell 34% year-over-year to $604 million, primarily due to price reductions resulting from the redesign of Medicare Part D in the United States.

Denosumab: Facing biosimilar erosion for the first time in the U.S. Sales of the osteoporosis treatment brand Prolia fell by 4% to $1.1 billion, while sales of the bone cancer treatment brand Xgeva dropped by 5% to $532 million. With three biosimilars expected to enter the market, sales of both brands are anticipated to continue eroding in the second half of this year.